Track the HLS Therapeutics Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in Canada. Shares trade on the CA market, under the oversight of SEDI. Market capitalisation: €122m. The latest transaction was disclosed on 18 August 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Millian, Craig. All data is free.
17
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HLS Therapeutics Inc. Strong Buy (bullish), based on 4 analysts. Average price target: CA$7.33.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,747 of 28,717 companies
44.8
score / 100
Value
52
Quality
38
FCF yld13%
Earn yld-10%
EV/EBITDA10.6x
ROE-14%
Gross mgn82%
Net mgn-22%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,000 shares@ CA$4.30100.0% of flowCommon SharesTSXSEDI:4736753
Canonical exit: 14 Sept 2026 (T+90)
17 of 17 declarations
About HLS Therapeutics Inc.
HLS Therapeutics Inc. is a Canadian pharmaceutical company focused on the development and commercialization of treatments for chronic diseases. It is listed on the Toronto Stock Exchange under the symbol HLS.